Moreover, reduced CYP8B1 activity in patients with CYP8B1 loss-of-function mutations was associated with decreased insulin resistance, which is a risk factor for NAFLD [27]. The gene discussed is CYP8B1; the disease is metabolic dysfunction-associated steatotic liver disease.